



Alkermes to Webcast R&D Day on Tuesday, April 7, 2009

March 24, 2009

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 24, 2009-- Alkermes, Inc. (NASDAQ: ALKS) today announced that it will webcast its Research and Development (R&D) Day meeting being held on Tuesday, April 7, 2009 at Alkermes' headquarters in Cambridge, Massachusetts. The webcast will begin at 8:30 a.m. EDT and will run until approximately 10:30 a.m. EDT. At the meeting, members of the Alkermes team and guest speakers will provide an update on the company's proprietary pipeline and overview the scientific rationale underlying its R&D strategy.

A live webcast of the event will be available on the investor relations section of the company's website at www.alkermes.com. To ensure a timely connection to the webcast, it is recommended that users register at least 15 minutes prior to the scheduled webcast. This webcast will be archived for 14 days.

Alkermes, Inc. is a fully integrated biotechnology company committed to developing innovative medicines to improve patients' lives. Alkermes developed, manufactures and commercializes VIVITROL® for alcohol dependence and manufactures RISPERDAL® CONSTA® for schizophrenia. Alkermes' robust pipeline includes extended-release injectable, pulmonary and oral products for the treatment of prevalent, chronic diseases, such as central nervous system disorders, addiction and diabetes. Headquartered in Cambridge, Massachusetts, Alkermes has research facilities in Massachusetts and a commercial manufacturing facility in Ohio.

Source: Alkermes

Eva Stroynowski
Corporate Communications
Alkermes, Inc.
(617) 583-6823